This phase II trial studies how well donor peripheral blood stem cell (PBSC) transplant works in treating patients with hematologic malignancies.
SparkCures ID | 321 |
---|---|
Trial Phase | Phase 2 |
Enrollment | 46 Patients |
Treatments |
|
Tags |
|
Trial Sponsors |
|
Trial Collaborators |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Adverse cytogenetics for overall survival such as:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers